Good thing Blarcamesine hopes to treat dementia. Thank you.

Were you excited for Mid 2027 earliest? Two more years.......funny.
I hate when people say without the subject. I find women do that more often than men.

That's their timeline and that has nothing to do with the clock at MAA.

Go AVXL$$

except he uses his reading for FUD. Don't you know that?
He's FUD'd for more than 7 years ever since he showed up here.
Why????

oK, georgeiil.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176329301

There is a substantial unmet medical need for Schizophrenia.
And new FDA Chief Wants to Fast-Track Some Drugs, Use More AI.
It sounds two articles today cover the same thing: CNPV?

Wow, that can be faster than Fast Track? lol. We may want to go this route for A371 too; below is copied from FDA website re: Fast Track.
No schizophrenia? I think that's a serious condition.haha
Let's get all approved by 1Q 2026 including Rett.

AIDS, Alzheimer’s, heart failure and cancer are obvious examples of serious conditions. However, diseases such as epilepsy, depression and diabetes are also considered to be serious conditions.

Thanks,

We(SOTC) believe this group(Sigma-1 Europe consortium)will play a key role in clinical adoption of Blarcamesine post-approval. Anavex is listed as a sponsor to this event.

Thank you Mayo for your ability to connect so many dots beyond my imagination! : )

https://www.sotcanalytics.com/update-compendium-2025

And we got her.

Growing stronger and stronger ever, targeting the Sigma-1 receptor is!!!
Thanks.

$$$AVXL$$$

Bar was low; it is lower now.

patience, patience...........

Thank you, Dia for bringing that up and thank Dr. Chris Missling for building our presence in Europe hiring one by one!

Wow........what a history book you have produced! ..........with ai's help.
It will take a week to read all.
Thank you for sharing.

You were funny.😁 You are a true Anavex long I'd say.........👍️

There's 0% of withdrawl by Anavex IMO and if i calculate the odd for approval VS reject
97.4%/ (0.8% + 97.4%) = 99.2%
99%!!!!
trying to jack it up. : )

I believe your theory. When Doc had displayed his high level skills of trading years ago, people didn't like it but 'naive' me thought that he was just one of doctors with other skills like playing violin, for example.  Now I think he has an agenda when I see him insisting on a 2%,3%,4% chance of EMA approval at this juncture. He has revealed himself.

Yup. I'm repeating myself....... 9 out of 10 clinical stage biostocks in my 10 year old watchlist have lost 95% to 99% excpet AVXL.
We are getting close.

AVXL$$

Does that mean that the shorts think SP will go down further?
Or they're building The Short Covering of the Year?
Maybe both. : )

AVXL$$

Wow....... so it means MAA approval = FDA approval if the "RESULT ACT" is passed.
Patiently waiting for the day
ANVX$$

For 6 years! That's a long term employment.

Thank you for sharing. The commonly estimated MC of $20 billion for AVXL doesn't acount for those countries that AI listed I think. I noticed that China and India are not included on the list while I see often Chinese scientists on the AD related articles. The populations of the two biggest country would be more that 1/3 of the world population.

I think ADPD 2022 came a year after the spike $31 pps which was thought to be a piggyback ride on SAVA developement.

Thank you for sharing the answer from Charles Schwab.
I often read suggestion on mesage boards of putting a limit sell order at unreachable price to prevent your shares from being lent out for shorting.

Dr. Missling and Dr. Marwan reposted "Amature" analyst MayoMobile's peer review summaries on Linkedin.
Isn't that somethin? : )

https://www.linkedin.com/posts/jesse-silveira-1a366927b_blarcamesine-for-the-treatment-of-early-alzheimers-activity-7283575477351374849-YNY5/?utm_source=share&utm_medium=member_ios

Congrats! You are a luck one. Many of us has been in for 10 years.

The title of an article by him is intersting:
(click the collection of his articles on AVXL at the bottom in the link and scroll down)

The Ticket to Approval of Balracamesine is The OLE Data
Jul 29, 2024

Sab, What's the timeframe to reach that number on your chart? 

Blarcamesine improved scores on Alzheimer’s-specific quality-of-life metrics by as much as 50%.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175509893

I'm just amazed that he has posted total 5290 messages for the last 7 years (or average 2 posts everyday including weekends and holidays) on AVXL- a small bio company that he even does not believe in. What does drive him in doing such achievement? Go figure......
Copied from his very 1st post on 12/19/2017:

Thank you for all your D.D. and sahring it here.

You're late to join the party. 
No never too late. Welcome lol

This will end our wondering about Accelerated Approval, thank to Trulieve at Stocktwits this morning.

The video was posted 24 day ago. 
So let's not worry. Lol

Check the size of the trials for Donepazil and its side effects. 

Your definition of the 'bar' is different from the most here I guess. According to your definition the 'bar' for any non-revenue generating drug company is always high no matter how SOC drug in the same group is.
The efficacy of the current SOC for A/D disease, namely Donapezil, is so poor and lasts only 6-12 months; it can also cause side effects like nausea, vomiting, and diarrhea. The bar is low for any new drug for A/D.

Whaaaat? Bar is high? I've never heard such when it comes to Anavex.
Donapezil set the low bar and Leqembi would lower the bar for an approval for Blarcamesine.

raja, are you watching on the fence by any chance?

Working hard on weekend. lol